Ipragliflozin is an orally active and highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus. It belongs to the gliflozin class of antidiabetic medicines and works by inhibiting glucose reabsorption in the proximal renal tubules, thereby increasing urinary glucose excretion and reducing blood glucose levels.
Ipragliflozin is also known by the development code ASP1941 and the brand-related name Suglat. The compound has the molecular formula C21H21FO5S and a molecular weight of 404.45 g/mol. Its CAS Number is 761423-87-4. Ipragliflozin is a glycoside and is characterized by a C-glucoside structure containing fluorine and sulfur.
Ipragliflozin is a small-molecule organic compound containing fluorine and sulfur. It is chemically described as a C-glucoside derivative containing a benzothiophene moiety. Ipragliflozin is generally supplied as a white to off-white powder or crystalline solid.
The reported molecular formula of Ipragliflozin is C21H21FO5S and its molecular weight is 404.45 g/mol. The reported melting point is approximately 155–157°C. It is slightly soluble in DMSO and methanol, while its aqueous solubility is limited.
Ipragliflozin selectively inhibits sodium-glucose cotransporter 2 (SGLT2), a transporter responsible for the majority of glucose reabsorption in the proximal renal tubules. Inhibition of SGLT2 reduces renal glucose reabsorption and increases urinary glucose excretion. This mechanism contributes to lowering blood glucose concentrations in patients with type 2 diabetes mellitus.
Ipragliflozin is used as an antidiabetic pharmaceutical ingredient for type 2 diabetes mellitus. It is an SGLT2 inhibitor and may be used as monotherapy or in combination with other antidiabetic therapies according to the applicable approved product information.
Ipragliflozin API can be characterized using chromatographic and spectroscopic analytical techniques. HPLC is commonly used for purity and assay determination, while identity may be confirmed using appropriate chromatographic, spectroscopic and mass-spectrometric techniques.
Commercial analytical-grade Ipragliflozin may be available with HPLC purity specifications such as not less than 98%, while pharmaceutical API specifications may differ according to the applicable manufacturer, pharmacopoeial requirements and approved product specification.
Ipragliflozin should be stored under controlled conditions appropriate for the supplied API. Commercial research material may be stored under refrigerated or frozen conditions depending on the supplier specification. The product should be protected from excessive heat, moisture and unsuitable environmental conditions.
Ipragliflozin API may be supplied for pharmaceutical development, formulation manufacturing, analytical testing and other qualified applications. Product specifications, Certificate of Analysis, batch details, packaging configuration and regulatory documentation should be confirmed according to the specific batch and intended application.
For Ipragliflozin API requirements, customers can request product specifications, analytical documentation, Certificate of Analysis, packaging information and commercial details. Quality parameters should be evaluated against the applicable approved or customer-specific specification before procurement.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 1.0% |
| Melting Point | 155–157°C |